{"id":"NCT01485796","sponsor":"Baxalta now part of Shire","briefTitle":"Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD","officialTitle":"Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-12-29","primaryCompletion":"2013-01-01","completion":"2013-01-01","firstPosted":"2011-12-06","resultsPosted":"2017-04-24","lastUpdate":"2021-05-19"},"enrollment":54,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immunodeficiency Diseases (PID)"],"interventions":[{"type":"BIOLOGICAL","name":"Immune Globulin Infusion (Human), 10%","otherNames":["IGI","10%"]},{"type":"BIOLOGICAL","name":"Recombinant human hyaluronidase","otherNames":["rHuPH20"]}],"arms":[{"label":"Epoch 1 and Epoch 2","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to acquire additional data on safety and tolerability of recombinant human hyaluronidase (rHuPH20) facilitated subcutaneous treatment of Immune Globulin Infusion (Human), 10% (IGI, 10%) and to assess the mode of product administration.\n\nFollowing a discussion with the FDA at the end of July 2012, all participants still active in the study stopped treatment with rHuPH20 to assure safety of the participants participating in the study and went into a safety follow-up.\n\nDuring this safety follow-up period, participants underwent treatment with the licensed product IGI, 10% (Gammagard Liquid). The intravenous or subcutaneous administration route was at the discretion of the participant and the investigator.","primaryOutcome":{"measure":"Number of Related Systemic Adverse Events (Excluding Infections)","timeFrame":"7 months (per subject)","effectByArm":[{"arm":"Safety Analysis Set (n=37)","deltaMin":59,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":18},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":37},"commonTop":["Infusion site pain","Headache","Infusion site erythema","Infusion site swelling","Pyrexia"]}}